Itraconazole, Posaconazole and Voriconazole in Serum/Plasma - HPLC

Clinical relevance

In recent years there has been an increase in invasive fungal infections due to the growing number of people with immunosuppression. Candida and Aspergillus are the most common types of infection, but previously rare fungal infections such as fusariosis or zygomycosis are also on the rise. Options for oral antimycotic therapy have improved considerably with the advent of new drugs. These include second-generation triazoles such as posaconazole and voriconazole.

Posaconazole is used primarily in case of therapy-resistant mycoses or drug intolerances. Voriconazole is also effective against some itraconazole-resistant Aspergillus species and offers fungicidal activity against emerging fungal pathogens such as Scedosporium or Fusarium. All three azoles exhibit wide inter-individual variability in bioavailability, so monitoring of drug levels is required.

Product advantages

• 3PLUS1® Multilevel Calibrator Set available
• Tri-level controls available
• Tailor-made internal standard

This Chromsystems assay allows for reliable chromatographic determination of itraconazole, its active metabolite hydroxy-itraconazole, and posaconazole and voriconazole in only one isocratic HPLC run with fluorescence detection. Two very simple and efficient protein precipitation steps are used to separate interfering components and to obtain stable eluates. A tailor-made internal standard ensures reliable and precise quantification of the analytes.

These analytes - together with 9 further antimycotics - can also be determined using LC-MS/MS with the TDM Parameter Set Antimycotic Drugs from the MassTox® TDM Series A.